- Home
- LGVN
LGVN
Longeveron Inc.
as 07-26-2024 4:00pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 31.2M | IPO Year: | 2021 |
| Target Price: | $12.00 | AVG Volume (30 days): | 11.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $35.60 | Next Earning Date: | 08-09-2024 |
| Revenue: | $978,000 | Revenue Growth: | -13.53% |
| Revenue Growth (this year): | 137.24% | Revenue Growth (next year): | 50.77% |
Stock Insider Trading Activity of Longeveron Inc. (LGVN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hashad Mohamed Wa'el Ahmed | LGVN | Chief Executive Officer | Apr 11 '24 | Buy | $2.35 | 10,638 | $24,999.30 | 19,616 | SEC Form 4 |
| Hare Joshua | LGVN | Chief Scientific Officer | Apr 10 '24 | Buy | $2.35 | 106,383 | $250,000.05 | 590,727 | SEC Form 4 |
| Hare Joshua | LGVN | Chief Scientific Officer | Apr 10 '24 | Buy | $2.35 | 42,553 | $99,999.55 | 633,280 | SEC Form 4 |
| Ross Cathy | LGVN | Director | Jan 10 '24 | Buy | $1.31 | 5,000 | $6,544.50 | 10,000 | SEC Form 4 |
| Baluch Khoso | LGVN | Director | Dec 28 '23 | Buy | $1.40 | 1,678 | $2,341.98 | 6,678 | SEC Form 4 |
| Baluch Khoso | LGVN | Director | Dec 28 '23 | Buy | $1.43 | 8,322 | $11,914.61 | 15,000 | SEC Form 4 |
| PFEFFER JEFFREY | LGVN | Director | Dec 28 '23 | Buy | $1.35 | 10,000 | $13,500.00 | 15,000 | SEC Form 4 |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Longeveron Raises $9 Million From Direct Offering
GlobeNewswire
7 days ago
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT Newswires
8 days ago
Longeveron Shares Decline After Pricing of $9 Million Direct Offering
GlobeNewswire
8 days ago
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MT Newswires
9 days ago
Longeveron Receives FDA's Fast Track Designation for Lomecel-B as Alzheimer's Treatment
GlobeNewswire
9 days ago
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
Zacks Small Cap Research
10 days ago
LGVN Gets Great FDA News for Alzheimer's Drug
Zacks Small Cap Research
11 days ago
OTC Markets Hosts Virtual Investor Presentation with Wa’el Hashad, CEO of Longeveron, and Brad Sorensen, Senior Analyst at Zacks SCR
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.